

Baseline And Follow Up

Subject ID

Date of Visit

Age at Visit

What type of visit is this?

- ☐ Baseline Visit
☐ Follow Up Visit
(Please make sure this matches the event name above)

Please make sure the above field matches the Event Name above (e.g. Follow Up Visit for Follow Up Visit 5).

Who filled out the paper CRF?**

- ☐ N/A
☐ Alex
☐ Ben
☐ Emily
☐ Jill
☐ Julia
☐ Katelyn
☐ Kellen
☐ Lori
☐ Meaghan
☐ Michael
☐ Raj
☐ Sarah
☐ Shelby
☐ Shiyun
☐ Unknown

Who entered the CRF directly into RedCap?**

- ☐ Alex
☐ Anastasia
☐ Julia
☐ Kate
☐ Knox
☐ Meaghan
☐ Raj
☐ Sarah
☐ Sean
☐ Spencer
☐ Shelby
☐ Sophia

Who has reviewed this?**

- ☐ Nobody
☐ An IBD Fellow
☐ Athos
☐ Scott

Date Entered**

Form BV: Baseline Visit

BV3. Date of initial IBD diagnosis

(Date of diagnostic colonoscopy, OR date of sigmoidoscopy, laparoscopy or surgery ONLY if treatment was started on that basis)

Age at Diagnosis

BV4. Visit Type

- _____
☐ Baseline Visit, within 3 months of initial IBD diagnosis
☐ Baseline Visit, > 3 months since initial IBD diagnosis

BV5. Date of Onset of Symptoms

(Calculate exactly based on the clinic note-- ie if it says the patient has had symptoms for about a year, use exactly one year prior. If a month is given, use the 15th of that month.)

Age at Onset of Symptoms

BV6. Initial IBD Diagnosis

- _____
☐ Crohn's Disease
☐ Ulcerative Colitis
☐ IBD Undefined

BV7. Has the patient had any GI surgical treatments?

- ☐ No
☐ Yes
(This is only the case if the patient is diagnosed at surgery.)

BV8. Has the patient had any IBD-related hospitalizations?

- ☐ No
☐ Yes
(This is only the case if the patient is diagnosed after being hospitalized.)

BV9. Has the patient been on any IBD-related medications?

- ☐ No
☐ Yes
(This is only the case if the patient has been put on IBD-related meds prior to diagnosis, either because of a perianal abscess or because IBD is strongly suspected before colonoscopy.)

Has the patient filled out the environmental/supplemental questionnaire?**

- ☐ No
☐ Yes

BV10. History obtained from (choose all that apply):

☐ Patient ☐ Parent or guardian ☐ Chart Review ☐ Other

Form FV: Follow Up Visit

FV3. Has IBD DIAGNOSIS TYPE changed since the last study visit?

- ☐ No
☐ Yes, prior IBD diagnosis type is:

FV4. Prior IBD diagnosis type:

- ☐ Crohn's Disease
☐ Ulcerative Colitis
☐ IBD Undefined

FV5. Current (new) IBD diagnosis type

- ☐ Crohn's Disease
☐ Ulcerative Colitis
☐ IBD Undefined

FV6. Does the patient's Jewish ANCESTRY information differ from the last study visit?

- ☐ No
☐ Yes

FV7. Has the patient's FAMILY HISTORY or BIRTH HISTORY changed since the last study visit?

- ☐ No
☐ Yes

FV8. Has the patient had any GI surgical treatments since the last study visit?

- ☐ No
☐ Yes

FV9. Has the patient had any IBD-related hospitalizations since the last study visit?

- ☐ No
☐ Yes

FV10. Has the patient been on or discontinued any IBD-related medications since the last study visit?

- ☐ No
☐ Yes

Has the patient's answers for the environmental/supplemental questionnaire changed?**

- ☐ No
☐ Yes

FV11. History obtained from:

☐ Patient ☐ Parent or guardian ☐ Chart Review ☐ Other

FV12. Physician's assessment of disease activity over the past year?

- ☐ Remission all year
☐ Intermittent flares, prednisone therapy needed, "step up" in treatment needed, etc
☐ Sick all year
(Despite the fact that this question has said "the last year," it should be over the whole interval history covered in the followup form. Remission all year: no flares, no hospitalizations, no steroids, may have mild baseline symptoms Sick all year: repeatedly in and out of the hospital, surgery, or never off steroids Intermittent: in between)

Form B: Jewish Ancestry

B1. Is patient of Jewish origin?

- ☐ No
☐ Yes

B1. Is patient of Jewish origin?

- ☐ No
☐ Yes

If yes, indicate Jewish ancestry subtype (choose all that apply):

☐ Sephardic ☐ Ashkenazi ☐ Unknown

Form C: Family History and Birth History

C1. Has anyone in the patient's family been diagnosed with Crohn's Disease, Ulcerative Colitis, or Unclassified IBD?

☐ No
☐ Yes

	Father	Mother	Son	Daughter	2nd degree relative	Brother	Sister	Twin
Crohn's Disease	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Ulcerative Colitis	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Unclassified IBD	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Identical

Crohn's Disease in Twin

☐

Ulcerative Colitis in Twin

☐

Unclassified IBD in Twin

☐

Fraternal

☐

☐

☐

C2. Have any of the patient's first degree relatives been diagnosed with a non-GI autoimmune disease?

☐ No
☐ Yes

If yes, choose all that apply

- ☐ Inflammatory Arthritis
☐ Diabetes Type 1
☐ Graves Disease/Hashimoto's Thyroiditis
☐ Psoriasis
☐ Systemic Lupus Erythematosus
☐ Vasculitis
☐ Other non-GI autoimmune disease

What non-GI autoimmune disease?

C2.5. Have any of the patient's first degree relatives been diagnosed with an immunodeficiency?**

☐ No
☐ Yes

If yes, choose all that apply

- ☐ Chronic granulomatous disease
☐ IL-10 receptor deficiency
☐ IPEX
☐ NEMO mutation
☐ Wiskott Aldrich
☐ X-Linked Agammaglobulinemia
☐ Other

What immunodeficiency?

C3. Do any of the patient's first degree relatives have a history of colon cancer?

☐ No ☐ Yes

C4. Was the patient breastfed?

☐ No
☐ Yes

C5. Approximate Duration of Breastfeeding (in months)

C5. Approximate Duration of Exclusive Breastfeeding (in months)**

☐ < 1 month
☐ 1-3 months
☐ 3-6 months
☐ >6 months

C6. Was the participant delivered by caesarean section?**

☐ No
☐ Yes

Form D: Smoking and Alcohol Use information

(For patients 18 and older only)

- D1. Has the patient used a tobacco product? ☐ Never used a tobacco product
☐ Yes
- D2. How recently has the patient used tobacco? ☐ Currently (within 2 months of this visit)
☐ Past only (quit more than 2 months prior to visit)
- D3. Number of years using tobacco? _____
- D4. If a smoker, how many packs per day has/was the patient using? ☐ Less than 1 pack
☐ 1-2 packs per day
☐ More than 2 packs per day
- D5. Has the patient ever used alcohol? ☐ Never used alcohol
☐ Yes
- D6. How recently has the patient used alcohol? ☐ Currently (within 2 months of this visit)
☐ Past only (quit more than 2 months prior to visit)
- D7. Number of years using alcohol? _____
- D8. Number of drinks per day the patient has/was using? ☐ Less than 1 drink per day
☐ 1-4 drinks per day
☐ More than 4 drinks per day

FORM E: Growth/Development

- E1. Current WEIGHT in kg (please indicate weight at diagnosis if this is a Baseline visit) _____
- E2. DATE on which Current Weight measured _____
- E3. Current HEIGHT in cm (please indicate height at diagnosis if this is a Baseline visit) _____
- E4. DATE on which Current Height measured _____
- E5. Previous WEIGHT in kg (please indicate a weight measured within one year prior to dates above) _____
(Use weight from 12 months ago if available; from 6-12 months ago if not.)
- E6. DATE on which Previous Weight measured _____
- E7. Previous HEIGHT in cm (please indicate a height measured within one year prior to dates above) _____
(Use height from 12 months ago if available; from 6-12 months ago if not.)
- E8. DATE on which Previous Height measured _____

Form F: IBD Disease Course

F1. Did the patient experience any IBD-related liver complications?

- ☐ No
☐ Yes

If yes, choose all that apply

- ☐ Drug induced hepatitis
☐ Steatohepatitis
☐ Primary Sclerosing Cholangitis (PSC)
☐ Autoimmune hepatitis
☐ Other liver complication

F2. Did the patient experience any IBD-related extra-intestinal manifestations?

- ☐ No
☐ Yes

If yes, choose all that apply

- ☐ Arthralgias (joint pain without arthritis)
☐ Arthritis / Spondyloarthritis / Spondylitis
☐ Erythema nodosum
☐ Pyoderma gangrenosum
☐ Uveitis
☐ Fever without source
☐ Other extra-intestinal manifestation

What other extra-intestinal manifestation?

F3. Did the patient experience any non-IBD autoimmune conditions?

- ☐ No
☐ Yes

If yes, choose all that apply

- ☐ Psoriasis
☐ Diabetes mellitus Type 1
☐ Celiac disease
☐ Autoimmune thyroiditis (Graves disease or Hashimoto thyroiditis)
☐ Systemic lupus erythematosus
☐ Other non-IBD autoimmune condition
(Other autoimmune conditions will be rare and severe. Allergies/asthma don't count)

What other non-IBD autoimmune condition?

F4. Did the patient experience any co-existing, non-treatment related immunodeficiency?**

- ☐ No ☐ Yes

Which immunodeficiency?

- ☐ Chronic granulomatous disease
☐ IL-10 receptor deficiency
☐ IPEX
☐ NEMO mutation
☐ Wiskott Aldrich
☐ X-Linked Agammaglobulinemia
☐ Other

What immunodeficiency?

Form G: Crohn's Disease Characteristics

G1. This form is being filled out for a:

- ☐ Baseline visit
☐ Follow Up (include INTERVAL studies, disease activity, and information ONLY)

If Baseline visit, this form is being filled out:

- ☐ within 3 months of initial IBD diagnosis
☐ more than 3 months since initial IBD diagnosis (also complete a 2nd form for follow-up)

G2. Which of the following studies have been done?

- ☐ Radiology (CT, MRI, upper GI/SBFT or fluoroscopy)
☐ EGD
☐ Colonoscopy
☐ Capsule study
☐ Not done
☐ Other

What other study? _____

G3. Was there evidence of disease activity in any of the following locations?

	Yes, Source of Evidence	No	Unknown
Esophagus	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Stomach	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Duodenum	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Jejunum	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ileum	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cecum or Ascending Colon	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Transverse Colon	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Descending Colon	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Sigmoid	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Rectum	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If Yes, Source of Evidence:

	Endoscopy	Histology	Radiology
Esophagus	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Stomach	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Duodenum	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Jejunum	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Ileum	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cecum or Ascending Colon	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Transverse Colon	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Descending Colon	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Sigmoid Colon	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Rectum	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

G4. Did the patient have any oropharyngeal disease:

(If followup, only include disease since the last visit. I.e. if oropharyngeal disease has healed, choose no.)

☐ No ☐ Yes ☐ Unknown

G5. Did the patient have any perianal disease:

(If followup, only include disease since the last visit. I.e. if perianal disease has healed, choose no.)

☐ No
☐ Yes

	No	Yes	Unknown
Skin Tags	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Fissure	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Fistula or abscess	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Stricture (Crohn's only; not surgery-related)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

G6. Did the patient have any of the following disease manifestations:

	No	Yes	Unknown
Mucosal/Inflammatory	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Stenosing/Strictureing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Fistulizing (excludes perianal)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

G7. If fistulizing, what type(s) of fistulas did the patient have?

	No	Yes	Unknown
Internal enteric fistula:	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Fistula to skin (non perianal):	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Vaginal or scrotal fistula:	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Fistula to bladder or urethra:	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

G8. Did the patient have any abdominal abscesses?

☐ No ☐ Yes ☐ Unknown

G9. Paris classification of Crohn's Disease - Age at diagnosis

☐ 0 to less than 10 years old ☐ 10 to less than 17 years old ☐ 17 to 40 years ☐ Greater than 40 years old

For G10, G11, and G12, you can only ever move up in Paris classifications; you can never move back down, even if disease heals.

G10. Paris classification of Crohn's Disease - Location

(Disease can be L1, L2, or L3 but not more than one. Disease can be any one of those and/or L4a and/or L4b.

Ligament of Treitz is between duodenum and jejunum, so L4b will be only visible through radiology. If only perianal or oral disease, there is no L categorization.)

☐ L1. Distal third ileum with or without limited cecal ☐ L2. Colonic ☐ L3. Ileocolonic ☐ L4a. Upper disease proximal to Ligament of Treitz ☐ L4b. Upper disease distal to ligament of Treitz and proximal to distal third ileum

G11. Paris classification of Crohn's Disease - Behavior

☐ B1. Non-stricturing and non-penetrating ☐ B2. Stricturing ☐ B3. Penetrating ☐ B2B3. Both structuring and penetrating, either at same or different times

B1 - Non-stricturing, non-penetrating disease: uncomplicated inflammatory disease without evidence of stricturing or penetrating disease.

B2 - Stricturing disease: the occurrence of constant luminal narrowing demonstrated by radiologic, endoscopic, or surgical examination combined with prestenotic dilation and/or obstructive signs or symptoms but without evidence of penetrating disease.

B3 - Penetrating disease: the occurrence of bowel perforation, intraabdominal fistulas, inflammatory masses and/or abscesses at any time in the course of the disease, and not secondary postoperative intra-abdominal complication (excludes isolated perianal or rectovaginal fistulae).

B2B3 - Stricturing and penetrating disease: the presence of both B2 and B3 phenotypes in the same patient, either at the same moment in time, or separately over a period of time.

G12. Paris classification of Crohn's Disease - Growth

(At Diagnosis: Difference between observed height z-score and the 'pre-illness' height z-score is >1.0. At Follow-Up: Reduction in height z-score since diagnosis is greater than or equal to 0.75.)

☐ No evidence of growth delay ☐ Growth delay

Form H: Crohn's Disease Pediatric CD Activity Index (PCDAI)

H1. Date of PCDAI assessment: _____

H2. How was this information obtained (choose all that apply):

☐ In person ☐ Phone ☐ Medical Record Review

H3. In the past week, how much did the patient experience abdominal pain?

- ☐ None (0)
☐ Brief, does not interfere with activities (5)
☐ Moderate to severe - daily, longer lasting, affects activities, nocturnal (10)

H4. In the past week, how many stools did the patient have per day?

- ☐ 0 to 1 liquid stools, no blood (0)
☐ Up to 2 semi-formed with small amount of blood, or 2-5 liquid stools (5)
☐ Gross bleeding, or 6 or more liquid stools, or nocturnal diarrhea (10)
 (If a patient has more than one stool a day but they are all formed and don't contain blood, score this as a 0.)

H5. In the past week, did the patient have any functional limitations?

- ☐ No limitations of activities, well (0)
☐ Occasional difficulty maintaining age appropriate activities, below par (5)
☐ Frequent limitation of activity, very poor (10)
 (If a patient is inpatient for an IBD flare, this is automatically a 10.)

H6. On examination, how was the patient's weight?

- ☐ Weight gain, or voluntary weight stable or voluntary weight loss (0)
☐ Involuntary weight stable, or involuntary weight loss 1 to 9 percent (5)
☐ Involuntary weight loss 10 percent or more (10)
 (In relation to the weight at the prior clinic visit)

H7. On examination, was there abdominal tenderness?

- ☐ No tenderness, no mass (0)
☐ Tenderness, or mass without tenderness (5)
☐ Tenderness, involuntary guarding, definite mass (10)
 (If a patient has distention, this does not count as abdominal tenderness/mass.)

H8. On examination, was there perirectal disease?

- ☐ None, asymptomatic tags (0)
☐ 1-2 indolent fistula, scant drainage, no tenderness (5)
☐ Active fistula, drainage, tenderness, or abscess (10)
 (Setons signify an indolent fistula.)

H9. On examination, were there any extra-intestinal manifestations?

- ☐ None (0)
☐ One (5)
☐ Two or more (10)
 (The only extra-intestinal manifestations included are: Fevers: 38.5 C for 3 days over past week, definite arthritis, uveitis, E. nodosum, P. gangrenosum)

H10. PCDAI Score (sum H3-H9)

H11. Severity of disease based on the PCDAI score:

- ☐ Clinical remission (score 0-10)
☐ Mild (score 11-25)
☐ Moderate-Severe (score 26-70)

Form I: Harvey-Bradshaw Activity Index

I1. Date of HBAI assessment:

I2. How was this information obtained (choose all that apply):

☐ In person ☐ Phone ☐ Medical Record Review

-Very well: no symptoms, except perhaps mild occasional bellyache or fatigue. (We can reference the ESR/CRP.)

-Slightly below par: Occasional diarrhea/fatigue

-Poor: Significant symptoms; tired, missing school occasionally, generally functioning

-Very poor: The "walking wounded." Daily pain, a lot of diarrhea, not making it to school

-Terrible: Inpatient (unless for a cleanout or a reason unrelated to CD)

Extraintestinal manifestations/active perianal disease can be factored into the global wellbeing assessment.

I3. General well-being:

- ☐ Very well (0)
☐ Slightly below par (1)
☐ Poor (2)
☐ Very poor (3)
☐ Terrible (4)

I4. Abdominal Pain:

- ☐ None (0)
☐ Mild (1)
☐ Moderate (2)
☐ Severe (3)

I5. Number of liquid stools per day:

(The number of unformed or partially formed stools each day. (Use the average if a range, and round up.))

I6. Abdominal mass:

- ☐ None (0)
☐ Dubious (1)
☐ Definite (2)
☐ Definite and Tender (3)

I7. Complications?

- ☐ No
☐ Yes

If yes, choose all that apply (1 point for each)

- ☐ Arthralgia
☐ Uveitis
☐ Erythema nodosum
☐ Aphthous ulcers
☐ Pyoderma gangrenosum
☐ Anal fissure
☐ New fistula
☐ Abscess

(If a patient has a complication, count each complication as 1 point.)

I8. HBAI Score (Sum I3-I7)

(If the number of liquid stools is not available, do not calculate.)

Form J: ULCERATIVE COLITIS or INDETERMINATE COLITIS characteristics

J1. This form is being filled out for a:

- ☐ Baseline visit
☐ Follow Up (include INTERVAL studies, disease activity, and information ONLY)

If Baseline, this form is being filled out:

- ☐ within 3 months of initial IBD diagnosis
☐ more than 3 months since initial IBD diagnosis (also complete a 2nd form for follow-up)

J2. Which of the following studies have been done?

(We do not need to note cecal patches or upper disease in UC patients.)

- ☐ Radiology (CT, MRI, upper GI/SBFT or fluoroscopy)
☐ EGD
☐ Colonoscopy
☐ Capsule study
☐ Not done
☐ Other

What other study?*

J3. Was there evidence of disease activity in any of the following locations? (Choose only the greatest extent of disease)

	Yes, Source of Evidence	No	Unknown
Proctitis (15 cm)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Left sided (splenic flexure)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pancolitis or subtotal colitis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If Yes, Source of Evidence

	Endoscopy	Histology	Radiology
Proctitis (15 cm)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Left Sided Colitis (splenic flexure)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Pancolitis or subtotal colitis	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

J4. Paris classification of Ulcerative Colitis - Extent

- ☐ Ulcerative proctitis
☐ Left-sided colitis (distal to splenic flexure)
☐ Extensive colitis (hepatic flexure distally)
☐ Pancolitis (proximal to hepatic flexure)
 (Patients can only move up in the Paris classifications; even if disease heals, they can never move back down.)

J5. Paris classification of Ulcerative Colitis - Severity

- ☐ Never severe
☐ Ever severe
 (Severe is defined by PUCAI greater than or equal to 65.)
-

Form K: UC or IBD-U Pediatric Ulcerative Colitis Activity Index (PUCAI)

K1. Date of PUCAI assessment:

 (Don't fill out a PUCAI for patients with pouches or ostomies.)

K2. How was this information obtained (choose all that apply):

☐ In person ☐ Phone ☐ Medical Record Review

K3. In the past week, how much did the patient experience abdominal pain?

- ☐ None (0)
☐ Pain can be ignored (5)
☐ Pain cannot be ignored (10)

K4. In the past week, how much rectal bleeding did the patient experience?

- ☐ None (0)
☐ Small amount only, in less than 50% of stools (10)
☐ Small amount with most stools (20)
☐ Large amount, >50% of stool content (30)

K5. In the past week, what was the consistency of most stools?

- ☐ Formed (0)
☐ Partially formed (5)
☐ Completely unformed (10)

K6. In the past week, what was the patient's stool frequency per day?

- ☐ 0-2 (0)
☐ 3-5 (5)
☐ 6-8 (10)
☐ >8 (15)

K7. In the past week, did any nocturnal stools cause the patient to awaken?

- ☐ No (0)
☐ Yes (10)

K8. In the past week, was the patient's activity level limited?

- ☐ No limitation of activity (0)
☐ Occasional limitation of activity (5)
☐ Severe restricted activity (10)

K9. PUCAI Score (Sum K3-K8)

K10. Severity of disease based on the PUCAI score:

- ☐ Clinical remission (score 0-9)
☐ Mild (score 10-34)
☐ Moderate (score 35-64)
☐ Severe (score 65-85)

Form L: Colon Cancer/Dysplasia Medical History

L1. Did the patient have a history of colon cancer?

- ☐ No
☐ Yes

L2. Did the patient have a history of colon polyps?

- ☐ No
☐ Yes
(Pseudopolyps don't count.)

L3. Did the patient have a history of colon dysplasia?

- ☐ No
☐ Yes

L4. Type of colon dysplasia:

- ☐ Flat
☐ Polypoid
☐ Unknown

L5. Grade of colon dysplasia:

- ☐ Indefinite
☐ Low Grade
☐ High Grade
☐ Unknown

Form Q: IBD-Related Medication History

Q1. Please indicate sources of information used to answer medication items

☐ Patient or family recall ☐ Limited chart review ☐ Provider recall ☐ Other

Q2. Aminosalicylates

- ☐ No, never been on ☐ Yes, current or past use
(If yes, choose one answer per medication)

	Current use	Prior use	Never	Unknown
Mesalamine (Asacol, Canasa, Pentasa, Rowasa, Apriso, Lialda, Delzicol)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Sulfasalazine (Azulfidine)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Balsalazide (Colazal)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Olsalazine (Dipentum)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q3. Non-biologic chemotherapeutic medications

☐ No, never been on use ☐ Yes, current or past use
(If yes, choose one answer per medication)

	Current use	Prior use	Never	Unknown
6-mercaptopurine (6-MP)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Azathioprine (Imuran)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Methotrexate (Folex, Rheumatrex, Mexate)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
FK-506 (Tacrolimus, Prograf)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cyclosporine A (Sandimmune, Neoral)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Thalidomide (Thalomid)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lenalidomide (Revlimid)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q4. Anti-TNF biologic medications

☐ No, never been on use ☐ Yes, current or past use
(If yes, choose one answer per medication)

	Current use	Prior use	Never	Unknown
Infliximab (Remicade)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Adalimumab (Humira)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Certolizumab pegol (Cimzia)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Golimumab (Simponi)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q5. Other biologic medications

☐ No, never been on use ☐ Yes, current or past use
(If yes, choose one answer per medication)

	Current use	Prior use	Never	Unknown
Natalizumab (Tysabri)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Tocilizumab (Actemra)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Vedolizumab (Entyvio)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ustekinumab (Stelara)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q6. Glucocorticoids

☐ No, never been on use ☐ Yes, current or past use
(If yes, choose one answer per medication)

	Current use	Prior use	Never	Unknown
Oral enteric steroids - Budesonide (Entocort)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Rectal steroids - Hydrocortisone enema (Colocort, Cortenema, Cortifoam)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Oral steroids - Prednisone, prednisolone (Prelone), methylprednisolone (Solumedrol)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Intravenous steroids - Methylprednisolone (Solumedrol)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

How many steroid courses (non-topical) has the patient had in the interval since the last visit?

Q7. Antibiotics (prescribed for IBD)

☐ No, never been on ☐ Yes, current or past use
(If yes, choose one answer per medication)

	Current use	Prior use	Never	Unknown
Metronidazole (Flagyl)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ciprofloxacin (Cipro)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Trimethoprim+Sulfamethoxazole (Bactrim)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Amoxicillin (Amoxil), Amoxicillin+Clavulanate (Augmentin)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Vancomycin (Vancocin)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q8. PSC medications

☐ No, never been on ☐ Yes, current or past use
(If yes, choose one answer per medication)

	Current use	Prior use	Never	Unknown
Ursodiol (Urso, Actigall)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cholestyramine (Prevalite, Questran)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Rifampin (Rifampicin)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q9. Enteral Feeding

☐ Never ☐ Prior use
☐ Current use ☐ Unknown

Q10. Supplements (Omega 3 or Probiotic)

☐ No, never been on ☐ Yes, current or past use
(If yes, choose one answer per medication)

	Current use	Prior use	Never	Unknown
Omega 3	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Probiotic	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Q11. Has the patient had a fecal transplant?

☐ No
☐ Yes

Form R: Discontinued IBD-Related Medications

R1. Please indicate sources of information used to answer medication items

☐ Patient or family recall ☐ Limited chart review ☐ Provider recall ☐ Other
R2. Aminosalicylates

	Lack of Response	Not Needed (in remission)	Adverse Event or Intolerance to Medication
Mesalamine (Asacol, Canasa, Pentasa, Rowasa, Apriso, Lialda, Delzicol)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Sulfasalazine (Azulfidine)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Balsalazide (Colazal)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Olsalazine (Dipentum)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

R3. Non-biological chemotherapeutic medications

	Lack of Response	Not Needed (in remission)	Adverse Event or Intolerance to Medication
6-mercaptopurine (6-MP)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Azathioprine (Imuran)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Methotrexate (Folex, Rheumatrex, Mexate)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
FK-506 (Tacrolimus, Prograf)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cyclosporine A (Sandimmune, Neoral)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Thalidomide (Thalomid)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lenalidomide (Revlimid)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
	Lack of Response	Not Needed (in remission)	Adverse Event or Intolerance to Medication
Infliximab (Remicade)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Adalimumab (Humira)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Certolizumab pegol (Cimzia)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Golimumab (Simponi)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

R5. Other biologic medications

	Lack of Response	Not Needed (in remission)	Adverse Event or Intolerance to Medication
Vedolizumab (Entyvio)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Natalizumab (Tysabri)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Tocilizumab (Actemra)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ustekinumab (Stelara)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

R6. Glucocorticoids

	Lack of Response	Not Needed (in remission)	Adverse Event or Intolerance to Medication
Oral enteric steroids - Budesonide (Entocort)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Rectal steroids - Hydrocortisone enema (Colocort, Cortenema, Cortifoam)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Oral steroids - Prednisone, prednisolone (Prelone), methylprednisolone (Solumedrol)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Intravenous steroids - Methylprednisolone (Solumedrol)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

R7. Antibiotics (prescribed for IBD)

	Lack of Response	Not Needed (in remission)	Adverse Event or Intolerance to Medication
Metronidazole (Flagyl)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ciprofloxacin (Cipro)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Trimethoprim+Sulfamethoxazole (Bactrim)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Amoxicillin (Amoxil), Amoxicillin+Clavulanate (Augmentin)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Vancomycin (Vancocin)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

R8. PSC Meds

	Lack of Response	Not Needed (in remission)	Adverse Event or Intolerance to Medication
Ursodiol (Urso, Actigall)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cholestyramine (Prevalite, Questran)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Rifampin (Rifampicin)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Adverse Event or Intolerance to Medication

Mesalamine (Asacol, Canasa, Pentasa, Rowasa, Apriso, Lialda, Delzicol)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Sulfasalazine (Azulfidine)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Balsalazide (Colazal)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Olsalazine (Dipentum)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

6-mercaptopurine (6-MP)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Azathioprine (Imuran)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Methotrexate (Folex, Rheumatrex, Mexate)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

FK-506 (Tacrolimus, Prograf)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Cyclosporine A (Sandimmune, Neoral)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Thalidomide (Thalomid)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Lenalidomide (Revlimid)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Infliximab (Remicade)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Adalimumab (Humira)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Certolizumab pegol (Cimzia)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Golimumab (Simponi)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Natalizumab (Tysabri)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Vedolizumab (Entyvio)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Ustekinumab (Stelara)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Tocilizumab (Actemra)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Oral enteric steroids - Budesonide (Entocort)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Rectal steroids - Hyrdocortisone enema (Colocort,
Cortenema, Coritfoam)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and dis-turbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malig-nant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leu-koencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insuffi-ciency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Oral Steroids - Prednisone, prednisolone (Prelone),
methylprednisolone (Solumedrol)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Intravenous steroids - Methylprednisolone
(Solumedrol)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Metronidazole (Flagyl)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Ciprofloxacin (Cipro)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Trimethoprim+Sulfamethoxazole (Bactrim)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Amoxicillin (Amoxil), Amox+Clavulanate (Augmentin)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Vancomycin (Vancocin)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Ursodiol (Urso, Actigall)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Cholestyramine (Prevalite, Questran)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Rifampin (Rifampicin)

- ☐ 10000496 Acne
- ☐ 10002199 Anaphylactic shock
- ☐ 10002424 Angioedema
- ☐ 10061663 Atypical mycobacterial infection
- ☐ 10004018 Bacterial infectious disorders
- ☐ 10048305 Birth defects
- ☐ 10008479 Chest pain
- ☐ 10012301 Demyelinating disease of central nervous system, unspecified
- ☐ 10012375 Depressed mood disorders and disturbances
- ☐ 10013710 Drug interaction
- ☐ 10058919 Drug rash with eosinophilia and systemic symptoms
- ☐ 10013762 Drug-induced hepatitis
- ☐ 10013706 Drug-induced lupus erythematosus
- ☐ 10013963 Dyspnea
- ☐ 10014418 Electrolyte imbalance
- ☐ 10014950 Eosinophilia
- ☐ 10015108 Epstein-Barr virus infection
- ☐ 10016256 Fatigue
- ☐ 10017528 Fungal infectious disorders
- ☐ 10017991 Gastrointestinal neoplasms malignant and unspecified
- ☐ 10018283 Gingival hyperplasia
- ☐ 10066476 Haematological malignancy
- ☐ 10019045 Hair loss
- ☐ 10019211 Headache
- ☐ 10066957 Hepatosplenic T-cell lymphoma
- ☐ 10019948 Herpes simplex
- ☐ 10019974 Herpes zoster
- ☐ 10020112 Hirsutism
- ☐ 10020635 Hyperglycaemia
- ☐ 10020772 Hypertension
- ☐ 10021027 Hypomagnesaemia
- ☐ 10021058 Hypophosphataemia
- ☐ 10021097 Hypotension
- ☐ 10021821 Infection in patient with acquired immune deficiency
- ☐ 10021879 Infections - pathogen unspecified
- ☐ 10051792 Infusion related reaction
- ☐ 10022095 Injection site reaction
- ☐ 10065048 Latent tuberculosis
- ☐ 10024384 Leukopenia
- ☐ 10024968 Lower respiratory tract infection
- ☐ 10025323 Lymphomas NEC
- ☐ 10026753 Manic and bipolar mood disorders and disturbances
- ☐ Nausea
- ☐ 10028997 Neoplasm malignant
- ☐ 10067571 Nephrotoxicity
- ☐ 10029331 Neuropathy peripheral
- ☐ Other
- ☐ 10033645 Pancreatitis
- ☐ 10033661 Pancytopenia
- ☐ 10035742 Pneumonitis
- ☐ 10036807 Progressive multifocal leukoencephalopathy
- ☐ 10037149 Pseudotumor cerebri
- ☐ 10037153 Psoriasis
- ☐ 10037844 Rash
- ☐ 10039807 Secondary adrenocortical insufficiency
- ☐ 10040998 Sleep disturbances (incl subtypes)
- ☐ 10042030 Stevens Johnson syndrome
- ☐ 10043607 Thrombosis
- ☐ 10049414 Treatment noncompliance
- ☐ 10049737 Treatment related secondary malignancy
- ☐ 10044755 Tuberculosis
- ☐ 10048302 Tubulointerstitial nephritis
- ☐ 10074465 Unable to afford prescribed medication

Other Medication Side Effect:

(Only use if the MedDRA is known)

FORM S: Labs

Date of Lab Reference

(For Baseline visits, this will be the Date of
Diagnosis. For Follow-Up visits, this will be the
Date of Visit)

When were labs taken?

(If labs were taken on multiple days, select the
date that the plurality of labs were taken on)

ALB (g/dL)

Alk Phos (U/L)

AST (U/L)

BUN (mg/dL)

Creatinine (mg/dL)

CRP (mg/dL)

ESR (mm/hr)

GGT (U/L)

HCT (%)

Hemoglobin (g/dL)

PLT (K cells/uL)

WBC (K cells/uL)

Form U: Environmental History/Supplemental Questions

Did the participant live at home with a smoker
anytime during the 6 month period prior to
diagnosis?

- ☐ No
☐ Yes

Did the participant live at home with a smoker at
anytime, more than 6 months prior to diagnosis?

- ☐ No
☐ Yes

Did the participant's biological mother smoke during
pregnancy?

- ☐ No
☐ Yes

Does the patient have a long term history of
antibiotic use prior to diagnosis?

- ☐ No
☐ Yes
(Long term history > 6 weeks)

If yes, how many months was the longest course?

Does the patient have a long term history of steroid
use prior to diagnosis?

- ☐ No
☐ Yes
(Long term history > 6 weeks)

If yes, how many months was the longest course? _____

FORM V: VEOIBD Specific Questions

Does the patient have these intestinal disease manifestations?

- ☐ Abdominal Pain
- ☐ Diarrhea
- ☐ Linear Growth Failure
- ☐ Malaise
- ☐ Rectal Bleeding
- ☐ Weight Loss

Participant's country of birth (if not USA): _____

Estimated date of arrival in the U.S. _____

(N/A for patients who never visit children's)

Has the participant had recurrent/persistent folliculitis?

- ☐ No
- ☐ Yes

Does the participant have documented cows' milk protein allergy?

- ☐ No
- ☐ Yes

Is there a family history of consanguinity?

- ☐ No
- ☐ Yes

Does the patient have a history of oral or perianal disease?

- ☐ Oral
- ☐ Perianal
- ☐ Neither

Did the patient receive NSAIDs any time during the 6 month period prior to Diagnosis?

- ☐ No
- ☐ Yes

How many doses of NSAIDs?

- ☐ < 3
- ☐ 3-6
- ☐ 7-20
- ☐ 21-30
- ☐ >30

Did the patient have a severe gastrointestinal infection (e.g: C. Diff., Salmonella) within 6 months of diagnosis?

- ☐ No
- ☐ Yes

PLEASE REMEMBER TO FILL OUT THE HOSPITALIZATION/SURGERY FORMS FOR THIS PATIENT.